1. Sepracor, Inc. (15 from 322 patents)

2. Rhone-poulenc Rorer Pharmaceuticals Inc. (13 from 111 patents)

3. Aventis Pharmaceuticals Inc. (4 from 207 patents)

4. Aventis Pharmaceuticals Products Inc. (1 from 23 patents)

5. Rhone-poulenc Rorer International (holdings), Inc. (1 from 2 patents)

6. Aventis Pharmaceuticals Product, Inc. (1 from 1 patent)

1. 7816375 - Ligands for monoamine receptors and transporters, and methods of use thereof

2. 7550597 - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases

3. 7517892 - Ligands for monoamine receptors and transporters, and methods of use thereof

4. 7511141 - Piperidine-piperazine ligands for neurotransmitter receptors

5. 7446115 - Peptidomimetic ligands for cellular receptors and ion channels

6. 7294637 - Method of treating addiction or dependence using a ligand for a monamine receptor or transporter

7. 7132551 - Ligands for monoamine receptors and transporters, and methods of use thereof

8. 7115664 - Peptidomimetic ligands for cellular receptors and ion channels

9. 7087623 - Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof

10. 6992077 - Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof

11. 6936614 - Piperidine-piperazine ligands for neurotransmitter receptors

12. 6846815 - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases

13. 6762177 - Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof

14. 6713479 - Piperidine-piperazine ligands for neurotransmitter receptors

15. 6699866 - Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof